The FDA has cleared an investigational new drug application allowing United Therapeutics to begin SUMMIT, a 16-week phase 2 trial of inhaled treprostinil delivered by soft mist inhaler in roughly 40 patients with pulmonary hypertension secondary to COPD. The primary endpoints are safety and tolerability, with exercise capacity and NT-proBNP as secondary measures. No approved therapy currently exists for this condition, which the company estimates affects 400,000 to 800,000 people in the US.
Key Points
- Phase 2 trial tests inhaled treprostinil in 40 PH-COPD patients
- Safety and tolerability primary; exercise capacity and NT-proBNP secondary
- Phase 3 registration study not expected before 2028
Longevity Analysis
Pulmonary hypertension in COPD illustrates how one failing system masks another: breathlessness and reduced exertion are attributed to airway disease while rising pressure in the pulmonary arteries progresses unmeasured, because right heart catheterization is not recommended in stable COPD. The consequence is a vascular problem misread as a purely respiratory one, and a population of several hundred thousand with no approved therapy. Interpretation matters as much as intervention here — a delivery device designed to avoid cough and bronchospasm, dosed four times daily, is only useful once the underlying circulatory burden is correctly identified and the regimen sustained long enough to register a change in functional capacity.
Original published by Longevity.Technology, by Kyle Umipig.